Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Comments on India Regulatory Agency Decision to Ban Actos
New York, New York (PRWEB) July 13, 2013 -- As Actos bladder cancer lawsuit claims continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that India’s drug regulator has decided to ban Actos. According to a June 27th report from India Today, the Ministry of Health and Family Welfare enacted a ban on Actos and other forms of poglitazone under the country’s Drugs and Cosmetic Act, citing its association with bladder cancer and congestive heart failure.*
“We have heard from numerous individuals seeking to file Actos lawsuits that allege the drug caused their bladder cancer. Considering recent research pointing to a link between Actos and the disease, it is not surprising that India took this step,” says Bernstein Liebhard LLP, nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed the disease after using the medication for an extended period of time.
Actos Lawsuits
Actos is approved to lower blood sugar in patients with type 2 diabetes. In June 2011, the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer.** According to Bloomberg.com, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.***
According to an update issued by the U.S. Judicial Panel on Multidistrict Litigation on July 10th, more than 2,400 Actos lawsuits are pending in a consolidated proceeding underway in U.S. District Court, Western District of Louisiana. All of the claims filed in the litigation allege long-term use of Actos may cause or worsen bladder cancer. Plaintiffs further allege that Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer. The first trial in the federal Actos litigation is scheduled to begin on January 27, 2014. (In re: Actos Product Liability Litigation, MDL No. 2299)
Additional Actos bladder cancer lawsuits have also been filed in various federal courts around the country. In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Long-term users of Actos who have been diagnosed with bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.
*indiatoday.intoday.in/story/govt-bans-drugs-anti-diabetes-analgin-pioglitazone-anti-depressant-deanxit-drugs-and-cosmetic-act/1/285575.html
**fda.gov/drugs/drugsafety/ucm259150.htm, FDA, June 15, 2011
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html, Bloomberg, March 5, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com
Felecia L. Stern, Bernstein Liebhard LLP, http://www.consumerinjurylawyers.com, 800-511-5092, [email protected]
Share this article